Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...
“Regeneron continues to diversify our commercial ... Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two or more lines of systemic therapy, but ...
Regeneron collaborates with Truveta and leading ... Odronextamab (CD20xCD3) for lymphoma: Ordsponoâ„¢ (odronextamab) has been approved in the European Union for relapsed/refractory follicular ...
Odronextamab is approved in the European Union as Ordsponoâ„¢ to treat R/R FL or DLBCL after two or more lines of systemic therapy, but the safety and efficacy of odronextamab has not been fully ...
Regeneron recently announced that the primary ... The drug has been approved under the brand name Ordspono. However, the company’s efforts to get odronextamab approved in the United States ...
This remarkable peak reflects a significant... ByInvesting.com • 27 Aug 2024 Regeneron shares reiterated at Buy at TD Cowen on Ordspono optimism On Monday, TD Cowen maintained a positive stance on ...